<p>Guardant Health, Inc.（纳斯达克代码：GH - 获取免费报告）董事 Musa Tariq 于 3 月 18 日（星期三）出售了 348 股该公司的股票。股票的平均售价为 88.09 美元，总交易额为 30,655.32 美元。出售后，该董事持有 8,394 股公司的股票，估值约为 739,427.46 美元。此次交易使其持股减少了 3.98%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>Guardant Health</strong> 的提醒：</p>
<h2>Guardant Health 股价上涨 2.1%</h2>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多机会</li>
</ul>
<p>周四，GH 股价上涨 1.81 美元，达到 89.08 美元。该公司的交易量为 1,228,613 股，而其平均交易量为 2,012,589 股。该公司的 50 日移动平均价格为 102.70 美元，200 日移动平均价格为 90.31 美元。Guardant Health, Inc.的 1 年最低价为 36.36 美元，1 年最高价为 120.74 美元。该公司的市值为 116.8 亿美元，市盈率为-26.91，贝塔值为 1.67。</p>
<p>Guardant Health（纳斯达克代码：GH - 获取免费报告）最近于 2 月 19 日（星期四）发布了季度财报。该公司报告本季度每股收益（EPS）为-0.50 美元，低于市场共识预期的-0.43 美元，差额为 0.07 美元。该公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。在去年同期，该公司每股收益为-0.62 美元。该公司本季度的收入同比增长 39.4%。分析师平均预测，Guardant Health, Inc.在当前年度的每股收益将为-2.9。</p>
<h2>Guardant Health 的机构交易</h2>
<ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
<p>一些对冲基金最近增持或减持了 GH 的股份。V Square Quantitative Management LLC 在第四季度新购入了 Guardant Health 的股份，价值约 27,000 美元。Chesapeake Asset Management LLC 在第四季度新购入了 Guardant Health 的股份，价值约 28,000 美元。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度新购入了 Guardant Health 的股份，价值约 31,000 美元。Elyxium Wealth LLC 在第四季度新购入了 Guardant Health 的股份，价值约 35,000 美元。最后，Parallel Advisors LLC 在第四季度将其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 目前持有该公司 352 股股票，价值 36,000 美元，此前在上个季度又购买了 219 股。92.60% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师的看法</h2>
<p>几位研究分析师最近对 GH 股票发布了报告。Weiss Ratings 在 1 月 22 日的报告中重申了对 Guardant Health 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 在 2 月 20 日的研究报告中将 Guardant Health 的目标价从 125.00 美元上调至 135.00 美元，并给予该公司 “买入” 评级。瑞银集团在 1 月 30 日的报告中重申了 “买入” 评级，并对 Guardant Health 的目标价为 175.00 美元。Leerink Partners 在 2 月 20 日的研究报告中将 Guardant Health 的目标价从 170.00 美元上调至 180.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Stifel Nicolaus 在 2 月 20 日的报告中将 Guardant Health 的目标价从 120.00 美元上调至 130.00 美元，并给予该公司 “买入” 评级。21 位分析师对该股票给予了买入评级，1 位给予了持有评级，1 位给予了卖出评级。根据 MarketBeat 的数据，Guardant Health 目前的平均评级为 “适度买入”，平均目标价为 122.57 美元。</p>
<ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
<p><strong>阅读我们对 Guardant Health 的最新股票分析</strong></p>
<h2>关于 Guardant Health</h2>
<p>（获取免费报告）</p>
<p>Guardant Health, Inc.是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA（ctDNA）对实体肿瘤患者的基因组变化进行分析。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据，推动癌症护理的进步。</p>
<p>该公司的旗舰产品 Guardant360 是一种下一代测序（NGS）检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Guardant Health 的董事 Musa Tariq 出售了 348 股，价格为每股 88.09 美元，总计 30,655.32 美元，代表其持股减少了 3.98%。出售后，他持有 8,394 股，估值约为 739,427.46 美元。该交易已向美国证券交易委员会（SEC）披露。Guardant Health 的股票最近交易价格为 89.08 美元，市值为 116.8 亿美元。分析师的评级意见不一，平均目标价共识为 122.57 美元，显示出 “适度买入” 的评级。该公司专注于基于血液的癌症诊断，并在最近的财报中报告了同比 39.4% 的收入增长</p>

<p>Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 348 shares of the firm's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director owned 8,394 shares of the company's stock, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Guardant Health, Inc.（纳斯达克代码：GH - 获取免费报告）董事 Musa Tariq 于 3 月 18 日（星期三）出售了 348 股该公司的股票。股票的平均售价为 88.09 美元，总交易额为 30,655.32 美元。出售后，该董事持有 8,394 股公司的股票，估值约为 739,427.46 美元。此次交易使其持股减少了 3.98%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 的提醒：</p>
</div><h2>Guardant Health Trading Up 2.1%</h2>
<div class="lb-trans"><h2>Guardant Health 股价上涨 2.1%</h2>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多机会</li>
</ul>
</div><p>GH traded up $1.81 on Thursday, hitting $89.08. The company had a trading volume of 1,228,613 shares, compared to its average volume of 2,012,589. The company's fifty day moving average price is $102.70 and its 200 day moving average price is $90.31. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The firm has a market cap of $11.68 billion, a P/E ratio of -26.91 and a beta of 1.67.</p>
<div class="lb-trans"><p>周四，GH 股价上涨 1.81 美元，达到 89.08 美元。该公司的交易量为 1,228,613 股，而其平均交易量为 2,012,589 股。该公司的 50 日移动平均价格为 102.70 美元，200 日移动平均价格为 90.31 美元。Guardant Health, Inc.的 1 年最低价为 36.36 美元，1 年最高价为 120.74 美元。该公司的市值为 116.8 亿美元，市盈率为-26.91，贝塔值为 1.67。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克代码：GH - 获取免费报告）最近于 2 月 19 日（星期四）发布了季度财报。该公司报告本季度每股收益（EPS）为-0.50 美元，低于市场共识预期的-0.43 美元，差额为 0.07 美元。该公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。在去年同期，该公司每股收益为-0.62 美元。该公司本季度的收入同比增长 39.4%。分析师平均预测，Guardant Health, Inc.在当前年度的每股收益将为-2.9。</p>
</div><h2>Institutional Trading of Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的机构交易</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
</div><p>A number of hedge funds have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd &amp; Titak Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health during the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金最近增持或减持了 GH 的股份。V Square Quantitative Management LLC 在第四季度新购入了 Guardant Health 的股份，价值约 27,000 美元。Chesapeake Asset Management LLC 在第四季度新购入了 Guardant Health 的股份，价值约 28,000 美元。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度新购入了 Guardant Health 的股份，价值约 31,000 美元。Elyxium Wealth LLC 在第四季度新购入了 Guardant Health 的股份，价值约 35,000 美元。最后，Parallel Advisors LLC 在第四季度将其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 目前持有该公司 352 股股票，价值 36,000 美元，此前在上个季度又购买了 219 股。92.60% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several research analysts have recently issued reports on GH shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Guardant Health in a report on Thursday, January 22nd. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 20th. UBS Group reissued a &#34;buy&#34; rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Leerink Partners lifted their target price on Guardant Health from $170.00 to $180.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 20th. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Guardant Health currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $122.57.</p>
<div class="lb-trans"><p>几位研究分析师最近对 GH 股票发布了报告。Weiss Ratings 在 1 月 22 日的报告中重申了对 Guardant Health 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 在 2 月 20 日的研究报告中将 Guardant Health 的目标价从 125.00 美元上调至 135.00 美元，并给予该公司 “买入” 评级。瑞银集团在 1 月 30 日的报告中重申了 “买入” 评级，并对 Guardant Health 的目标价为 175.00 美元。Leerink Partners 在 2 月 20 日的研究报告中将 Guardant Health 的目标价从 170.00 美元上调至 180.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Stifel Nicolaus 在 2 月 20 日的报告中将 Guardant Health 的目标价从 120.00 美元上调至 130.00 美元，并给予该公司 “买入” 评级。21 位分析师对该股票给予了买入评级，1 位给予了持有评级，1 位给予了卖出评级。根据 MarketBeat 的数据，Guardant Health 目前的平均评级为 “适度买入”，平均目标价为 122.57 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Guardant Health 的最新股票分析</strong></p>
</div><h2>About Guardant Health</h2>
<div class="lb-trans"><h2>关于 Guardant Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc.是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA（ctDNA）对实体肿瘤患者的基因组变化进行分析。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据，推动癌症护理的进步。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>该公司的旗舰产品 Guardant360 是一种下一代测序（NGS）检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock

Market Beat

Guardant Health

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因免疫&健康关怀 ETF - iShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

内幕交易：Guardant Health（纳斯达克代码：GH）的一位董事出售了 348 股股票